NEW YORK (GenomeWeb) – Signal Genetics today announced that is has signed an agreement to make its MyPRS assay available to 22 million patients covered by America's Choice Provider Network (ACPN).
MyPRS is microarray-based prognostic test for multiple myeloma and stratifies patients into molecular subtypes and into high- and low-risk categories using gene expression profiling.
"[W]e expect increased reimbursement support for our assay through agreements such as this to have a positive impact on our revenue generation over the long term," Signal Genetics CFO Tamara Seymour said in a statement. "As part of our overall growth strategy, we will continue to seek out these types of opportunities to ensure stable reimbursement as we work to make MyPRS available for physicians and patients across the US."
In April, Carlsbad, California-based Signal Genetics received accreditation from the College of American Pathologists for its laboratory in Little Rock, Arkansas.